Home » Stocks » APVO

Aptevo Therapeutics Inc. (APVO)

Stock Price: $17.89 USD -0.45 (-2.46%)
Updated Aug 3, 2021 1:24 PM EDT - Market open
Market Cap 83.52M
Revenue (ttm) 6.73M
Net Income (ttm) -27.90M
Shares Out 4.42M
EPS (ttm) -7.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $17.89
Previous Close $18.34
Change ($) -0.45
Change (%) -2.46%
Day's Open 18.43
Day's Range 17.78 - 18.60
Day's Volume 6,691
52-Week Range 6.17 - 60.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SEATTLE, WA / ACCESSWIRE / July 16, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its...

2 weeks ago - Accesswire

SEATTLE, WA / ACCESSWIRE / June 30, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its...

1 month ago - Accesswire

SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its...

1 month ago - Accesswire

Aptevo Therapeutics Inc. (APVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...

1 month ago - Zacks Investment Research

Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial SEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO)...

2 months ago - Accesswire

Aptevo Therapeutics Inc (NASDAQ: APVO) has announced positive results from Phase 1 dose-escalation trial evaluating lead ADAPTIR candidate, APVO436, for acute myeloid leukemia and myelodysplastic syndro...

2 months ago - Benzinga

Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving CD123-Target...

2 months ago - Accesswire

Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo Therape...

2 months ago - Accesswire

SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietar...

3 months ago - Accesswire

Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing Completes Sale of RUXIENCE Royalty Payments for Up F...

4 months ago - Accesswire

SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology thera...

6 months ago - Accesswire

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6 months ago - Zacks Investment Research

Aptevo went up hugely on positive phase 1 data in AML. The company develops bispecific antibodies against cancer.

8 months ago - Seeking Alpha

LUND, Sweden and SEATTLE, Nov. 16, 2020 /PRNewswire/ -- Alligator Bioscience ("Alligator") (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed...

8 months ago - PRNewsWire

Aptevo Therapeutics (APVO) news for Wednesday includes APVO stock taking a fall after a strong rally yesterday on clinical trial results. The post Aptevo Therapeutics News: Why APVO Stock Is Falling 15%...

8 months ago - InvestorPlace

The stock price of Aptevo Therapeutics Inc (NASDAQ: APVO) increased by 78.25% as it went from $6.30 at the close on Monday to $11.23 at the close on Tuesday. This is why it happened.

8 months ago - Pulse2

Markets took off this morning following more good news regarding coronavirus vaccines. Less-than-good earnings are expected for corporations, but it doesn't seem that way when looking at the major three...

Other stocks mentioned: BLNK, EFOI, EYES, SGBX
1 year ago - Forbes

Aptevo Therapeutics Inc. (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Is (APVO) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

SEATTLE and LUND, Sweden, June 10, 2020 /PRNewswire/ -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary...

1 year ago - PRNewsWire

Aptevo Therapeutics Inc (NASDAQ: APVO) shares are trading higher on Tuesday, after the company announced it regained compliance with the NASDAQ listing requirements.

1 year ago - Benzinga

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the U...

1 year ago - GlobeNewsWire

Aptevo announced preliminary Q3'19 product revenue for its Hemophilia B drug IXINITY will be about $9M.

1 year ago - Seeking Alpha

Reports Record Quarterly IXINITY® Net Revenue and New Patient Conversions  Following Launch of New 3,000 IU Assay

1 year ago - GlobeNewsWire

New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific Antibody Targeting 4-1BB and OX40

1 year ago - GlobeNewsWire

IXINITY revenue increased for the quarter, which is what I wanted to see.

1 year ago - Seeking Alpha

Investors might want to pay attention to Aptevo Therapeutics over the next several weeks before the company's Q2 results.

2 years ago - Seeking Alpha

About APVO

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, ... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
APVO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for APVO stock is "Buy." The 12-month stock price forecast is 61.00, which is an increase of 241.01% from the latest price.

Price Target
$61.00
(241.01% upside)
Analyst Consensus: Buy